1W7H

p38 Kinase crystal structure in complex with small molecule inhibitor

1W7H の概要

• エントリーDOI: 10.2210/pdb1w7h/pdb
• 関連するPDBエントリー: 1A9U 1BL6 1BL7 1BMK 1DI9 1IAN 1KV1 1KV2 1M7Q 1OUK 1OUY 1OVE 1OZ1 1R39 1R3C 1W82 1W83 1W84 1WFC
• 分子名称: MITOGEN-ACTIVATED PROTEIN KINASE 14, 3-(BENZYLOXY)PYRIDIN-2-AMINE (3 entities in total)
• 機能のキーワード: p38, kinase, inhibitor complex, phosphorylation, serine/threonine-protein kinase, transferase
• 由来する生物種: HOMO SAPIENS (HUMAN)
• 細胞内の位置: Cytoplasm : Q16539
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 41543.43

構造登録者

Jhoti, H.,Gill, A.,Cleasby, A.,Devine, L. (登録日: 2004-09-02, 公開日: 2005-02-08, 最終更新日: 2023-12-13)

主引用文献

Hartshorn, M.J.,Murray, C.W.,Cleasby, A.,Frederickson, M.,Tickle, I.J.,Jhoti, H.
Fragment-Based Lead Discovery Using X-Ray Crystallography
J.Med.Chem., 48:403-, 2005

PubMed Abstract: Fragment screening offers an alternative to traditional screening for discovering new leads in drug discovery programs. This paper describes a fragment screening methodology based on high throughput X-ray crystallography. The method is illustrated against five proteins (p38 MAP kinase, CDK2, thrombin, ribonuclease A, and PTP1B). The fragments identified have weak potency (>100 microM) but are efficient binders relative to their size and may therefore represent suitable starting points for evolution to good quality lead compounds. The examples illustrate that a range of molecular interactions (i.e., lipophilic, charge-charge, neutral hydrogen bonds) can drive fragment binding and also that fragments can induce protein movement. We believe that the method has great potential for the discovery of novel lead compounds against a range of targets, and the companion paper illustrates how lead compounds have been identified for p38 MAP kinase starting from fragments such as those described in this paper.

PubMed: 15658854
DOI: 10.1021/JM0495778

実験手法

X-RAY DIFFRACTION (2.214 Å)